Resources and Support for You and Your Patients
Downloadable nursing/administration resources for LUTATHERA® (lutetium Lu 177 dotatate)
Find a treatment site
LUTATHERA treatment sites in the United States are shown below (map current as of August 1, 2019).
AAA PatientCONNECT™ provides services to support your patient’s access to LUTATHERA treatment. These may include:
Patient Financial Assistance*
- Uninsured patient assistance
- Copay assistance for patients with commercial insurance
- Insurance benefits verification
- Prior authorization
- Claims appeal
- Billing and coding
- Payer policy
For more information, and to download reimbursement resources, visit www.aaapatientconnect.com.
*Eligibility restrictions may apply. For full terms and conditions, please call AAA PatientCONNECTTM at 1-844-NETS-AAA. Patients who are enrolled in any type of government insurance or reimbursement programs are not eligible. As a condition precedent of the copayment support provided under this program, eg, copay refunds, participating patients and pharmacies are obligated to inform insurance companies and third-party payers of benefits they receive and the value of this program, as required by contract or otherwise. Void where prohibited by law or restricted.
†It is the provider’s responsibility to determine and submit accurate information on claims and comply with payer coverage, reimbursement, and claim submission rules. Information in this presentation does not represent any statement, promise, or guarantee by AAA about coverage, levels of reimbursement, payment, or charge.
IMPORTANT SAFETY INFORMATION1
WARNINGS AND PRECAUTIONS
The most common Grade 3-4 adverse reactions (≥ 4% with a higher incidence in LUTATHERA arm) observed in NETTER-1 were lymphopenia (44%), increased GGT (20%), vomiting (7%), nausea (5%), elevated AST (5%), increased ALT (4%), hyperglycemia (4%), and hypokalemia (4%).
In ERASMUS, the following serious adverse reactions have been observed with a median follow-up time of more than 4 years after treatment with LUTATHERA: myelodysplastic syndrome (2%), acute leukemia (1%), renal failure (2%), hypotension (1%), cardiac failure (2%), myocardial infarction (1%), and neuroendocrine hormonal crisis (1%). Patients should be counseled and monitored in accordance with the LUTATHERA Prescribing Information.
Somatostatin and its analogs competitively bind to somatostatin receptors and may interfere with the efficacy of LUTATHERA. Discontinue long-acting somatostatin analogs at least 4 weeks and short-acting octreotide at least 24 hours prior to each LUTATHERA dose. Administer short- and long-acting octreotide during LUTATHERA treatment as recommended.
To report SUSPECTED ADVERSE REACTIONS, contact Advanced Accelerator Applications USA, Inc. at 1-844-863-19301-844-863-1930, or email@example.com, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information.
Distributed by: Advanced Accelerator Applications USA, Inc., NJ 07041
References: 1. LUTATHERA® [prescribing information]. Millburn, NJ: Advanced Accelerator Applications USA, Inc.; July 2018.